AMLAcute myeloid leukemia.
NPM1m / KMT2A-rTwo genetic subtypes of AML (NPM1-mutated, KMT2A-rearranged) that depend on menin.
ven/azaVenetoclax with azacitidine, the usual treatment for people who can't have intensive chemotherapy.
7+3Standard intensive induction chemotherapy: cytarabine for 7 days with an anthracycline for 3.
CR, CRc, CR/CRhComplete remission; composite CR (CR plus remission with incomplete blood count recovery; definitions vary between studies); CR with full or partial count recovery.
ORROverall response rate: everyone who responded, including partial responses.
MRDMeasurable residual disease: leukemia still detectable by sensitive tests.
Differentiation syndromeA known inflammatory side effect of drugs that make leukemia cells mature.